EyePoint Pharmaceuticals Ownership | Who Owns EyePoint Pharmaceuticals?


OverviewForecastRevenueFinancialsChartTranscripts

EyePoint Pharmaceuticals Ownership Summary


EyePoint Pharmaceuticals is owned by 57.67% institutional investors, 2.77% insiders, and 39.56% retail investors. Cormorant asset management, lp is the largest institutional shareholder, holding 11.91% of EYPT shares. Federated Hermes Kaufmann R is the top mutual fund, with 3.35% of its assets in EyePoint Pharmaceuticals shares.

EYPT Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockEyePoint Pharmaceuticals57.67%2.77%39.56%
SectorHealthcare Stocks 232.01%10.74%-142.75%
IndustryBiotech Stocks 381.47%10.55%-292.02%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Cormorant asset management, lp8.32M11.91%$118.55M
Blackrock funding, inc. /de6.79M9.67%$124.01M
Suvretta capital management6.19M8.86%$88.18M
Federated hermes6.02M8.58%$109.94M
Adage capital partners gp5.56M7.95%$79.17M
Blackrock3.76M7.12%$32.75M
Franklin resources4.98M7.09%$90.93M
Vanguard group4.82M6.87%$88.10M
Tcg crossover management3.57M5.11%$50.87M
Paradigm biocapital advisors lp2.01M2.87%$28.56M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Cormorant asset management, lp8.32M8.18%$118.55M
Essex woodlands management1.08M6.23%$19.82M
Principia wealth advisory530.73K6.06%$9.70M
5am venture management1.05M5.48%$14.95M
Rosalind advisors690.00K4.43%$12.61M
Patient square capital lp780.00K3.05%$14.25M
Tcg crossover management3.57M2.50%$50.87M
Suvretta capital management6.19M2.26%$88.18M
Artia global partners lp628.37K1.42%$8.95M
Myda advisors300.00K0.92%$4.27M

Top Buyers

HolderShares% AssetsChange
Paradigm biocapital advisors lp2.01M0.81%2.01M
Blackrock funding, inc. /de6.79M0.00%1.82M
Orbimed advisors1.80M0.60%1.80M
Federated hermes6.02M0.18%1.60M
Vanguard group4.82M0.00%1.03M

Top Sellers

HolderShares% AssetsChange
Ra capital management---3.18M
Perceptive advisors---1.54M
Adage capital partners gp5.56M0.13%-1.24M
Octagon capital advisors lp---1.09M
Finepoint capital lp---1.08M

New Positions

HolderShares% AssetsChangeValue
Paradigm biocapital advisors lp2.01M0.81%2.01M$28.56M
Orbimed advisors1.80M0.60%1.80M$25.58M
Axa investment managers244.43K0.01%244.43K$3.48M
Brevan howard capital management lp60.64K0.00%60.64K$863.53K
Marex group47.78K0.01%47.78K$872.89K

Sold Out

HolderChange
Twin peaks wealth advisors-1.00
Assetmark-15.00
Continuum advisory-16.00
Coldstream capital management-21.00
Park place capital-23.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 2025112-30.00%40,465,600-42.11%570.58%64-15.79%24-46.67%
Sep 30, 20251569.86%65,594,5981.78%931.10%767.04%4322.86%
Jun 30, 2025147-5.16%68,901,914-5.62%980.90%71-12.35%38-15.56%
Mar 31, 20251574.67%74,070,140-0.48%1060.57%81-16.49%4691.67%
Dec 31, 20241482.78%74,156,37726.76%1361.18%9541.79%24-52.00%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Federated Hermes Kaufmann R2.77M3.35%733.00K
Federated Hermes Kaufmann Growth2.77M3.35%733.00K
Vanguard Total Stock Mkt Idx Inv2.60M3.14%-
Franklin Biotechnology Discv A(acc)USD2.19M2.65%-
Federated Hermes Kaufmann Small Cap Grow1.98M2.39%497.00K
Federated Hermes Kaufmann Small Cap A1.98M2.39%497.00K
Vanguard US Total Market Shares ETF1.56M2.27%-
iShares Russell 2000 ETF1.82M2.19%1.29M
Franklin Small Cap Growth SMA1.27M1.84%1.27M
Franklin US Small Cap Growth Equity1.28M1.55%110.25K

Recent Insider Transactions


DateNameRoleActivityValue
Mar 04, 2026Ribeiro Ramiro Chief Medical OfficerSell$43.57K
Feb 17, 2026Ribeiro Ramiro Chief Medical OfficerSell$36.55K
Jan 05, 2026Ribeiro Ramiro Chief Medical OfficerSell$727.32K
Dec 04, 2025Cormorant Asset Management, LP Former 10% OwnerSell$942.24K
Dec 04, 2025Lurker Nancy-Sell$140.48K

Insider Transactions Trends


DateBuySell
2026 Q1-3
2025 Q4-5
2025 Q3--
2025 Q24-
2025 Q1--

EYPT Ownership FAQ


Who Owns EyePoint Pharmaceuticals?

EyePoint Pharmaceuticals shareholders are primarily institutional investors at 57.67%, followed by 2.77% insiders and 39.56% retail investors. The average institutional ownership in EyePoint Pharmaceuticals's industry, Biotech Stocks , is 381.47%, which EyePoint Pharmaceuticals falls below.

Who owns the most shares of EyePoint Pharmaceuticals?

EyePoint Pharmaceuticals’s largest shareholders are Cormorant asset management, lp (8.32M shares, 11.91%), Blackrock funding, inc. /de (6.79M shares, 9.67%), and Suvretta capital management (6.19M shares, 8.86%). Together, they hold 30.44% of EyePoint Pharmaceuticals’s total shares outstanding.

Does Blackrock own EyePoint Pharmaceuticals?

Yes, BlackRock owns 7.12% of EyePoint Pharmaceuticals, totaling 3.76M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 32.75M$. In the last quarter, BlackRock increased its holdings by 977.52K shares, a 35.07% change.

Who is EyePoint Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

Cormorant asset management, lp is EyePoint Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 8.18% of its assets in 8.32M EyePoint Pharmaceuticals shares, valued at 118.55M$.

Who is the top mutual fund holder of EyePoint Pharmaceuticals shares?

Federated Hermes Kaufmann R is the top mutual fund holder of EyePoint Pharmaceuticals shares, with 3.35% of its total shares outstanding invested in 2.77M EyePoint Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools